FDA sends warning letter to Immucor

May 13 (Reuters) - U.S. health regulators issued a warning letter to Immucor Inc (BLUD.O: Quote, Profile, Research), citing problems with its manufacturing practices, sending the shares of the blood-testing products maker down 5 percent.

The letter posted on the U.S. Food and Drug Administration's website on Tuesday said Immucor failed to establish and maintain procedures to control product that does not conform to specified requirements.

In the letter dated May 2, the FDA cited a number of product lots that were released for distribution before completing certain investigations on them.

In a statement, Immucor said it was working diligently to respond to the FDA as soon as possible.

"The FDA has not ordered the recall of any of our products, or placed any limitations on the manufacture or distribution of any of our products," Chief Executive Gioacchino De Chirico said in the statement.

Shares of the company were trading down $1.47 at $26.49 in afternoon trade on Nasdaq. (Reporting by Aradhana Aravindan in Bangalore; Editing by Vinu Pilakkott)